A novel eyedrop formulation of dexamethasone was found to reduce swelling and improve vision in a Phase II trial of patients with diabetic macular oedema (DME).
Special to Ophthalmology Times®
Diabetic macular edema (DME) is a significant cause of vision loss in patients with diabetes.
The various multifocal choroidopathies differ in course, prognosis, and treatment. While the prognoses do differ, they are hopeful with early treatment in most cases.
The International Widefield Imaging Study Group (IWISG)—a physician panel with expertise in retinal imaging—has released recommenda
Deep learning, a type of artificial intelligence, uses algorithms to recognize patterns.
Anti-vascular endothelial growth factor (VEGF) agents—including aflibercept, bevacizumab, and ranibizumab—have ushered in a new era in the treatment of retinal and choroidal neovascularization.
New research has shown that a longer axial length (AL) may prove protective of incident diabetic retinopathy (DR).1